NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

HyGro,

The ECA was clinically appropriate and the P3 was exemplary, but if you disagree and prefer a randomized placebo design, you’re in luck! Here’s a placebo trial for you:

https://clinicaltrials.gov/ct2/show/NCT04201873






The PD1 combo study for recurrent GBM has not gotten the publicity that it deserves since the exemplary P3 stole the spotlight when it was published in JAMA Oncology.

This whole video is awesome, but my favorite part is the brief mention of the pembrolizumab combo study at UCLA. Skip to about timestamp 6:30 of the video to hear Dr. Toms highlight the PD1 combo survival data!

Murcidencel (DCVax-L) is discussed beginning at minute 40, to focus on Keytruda (pembrolizumab) plus DCVax in combo at UCLA, skip to minute 45:40

https://www.uclahealth.org/news/brain-cancer-discovery-clinical-trials





https://www.uclahealth.org/news/ucla-received-590-million-in-nih-funding-second-highest-total-for-academic-medical-centers-in-2020

https://www.fda.gov/science-research/advancing-regulatory-science/fda-nih-joint-leadership-council-charter



https://brownneurosurgery.com/breakthrough-brain-cancer-vaccine/

https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847